Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Organoid Company
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The Organoid Company provides validated organoid models for drug discovery and toxicology. Their platform integrates genome engineering with advanced lab automation and cell analysis to enable accurate disease modeling, predictive drug screening, and toxicity solutions. They support the progression of therapies from early discovery through preclinical studies but do not appear to have their own therapeutic candidates in clinical trials[2][9].
- Therapeutic areas
- Other
- Modalities
- Cell therapyInduced pluripotent stem cell derived therapy3D organoid models
- Industry
- Non-Drug Biotech
Beyond the preview
Go deeper on The Organoid Company.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on The Organoid Company.